Ascentage Pharma Group International has announced the presentation of pivotal data from a China registrational Phase II study of Lisaftoclax (APG-2575) monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who were refractory to Bruton's tyrosine kinase inhibitors (BTKis). The results, which were presented in an oral report at the 2025 American Society of Hematology $(ASH)$ Annual Meeting, showed that Lisaftoclax achieved a 62.5% objective response rate in heavily pretreated, BTKi-refractory patients, nearly half of whom had complex karyotype. The study also reported a median progression-free survival of 23.89 months, with no cases of tumor lysis syndrome observed. The data supported the new drug application (NDA) approval of Lisaftoclax by China's National Medical Products Administration in July 2025.